血友病の疫学的予測(~2024)

GlobalDataが発行した調査報告書(GDHCER091-15)
◆英語タイトル:EpiCast Report: Hemophilia - Epidemiology Forecast to 2024
◆商品コード:GDHCER091-15
◆発行会社(リサーチ会社):GlobalData
◆発行日:2015年10月6日
◆ページ数:46
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥439,450見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥878,900見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,318,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、血友病の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・血友病の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・血友病の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Hemophilia – Epidemiology Forecast to 2024

Summary

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease.

In 2014, the 9MM had 60,671 diagnosed prevalent cases of hemophilia A and hemophilia B, around 28% of which occurred in the US. The diagnosed prevalent cases of hemophilia in the 9MM are expected to increase slightly to 61,954 cases by 2024. The US will have the largest proportion of diagnosed prevalent cases of hemophilia A and hemophilia B in the 9MM in 2024 at 29.05%. Because hemophilia is an inherited condition, it requires lifelong treatment. Given the increase in the prevalence of hypertension, with advancing age and increasing life expectancy in hemophiliacs due to advances in treatment, the challenges faced by hemophiliacs and the need for more supportive treatments and care will increase in the near future.

GlobalData epidemiologists forecast the epidemiological trend for hemophilia using data from the WFH Annual Global Survey Report, which is considered the gold standard for hemophilia data. The World Health Organization (WHO) authenticates the WFH data for hemophilia and other bleeding disorders and provides the most accurate data possible for hemophilia globally. The WFH Global Survey Report uses uniform data collection methods for each national member organization (NMO), allowing for a meaningful comparison of the diagnosed prevalent cases across the markets. A major strength of this analysis lays in the use of country-specific data and a uniform methodology across the markets to forecast the prevalent cases of hemophilia.

Scope

- The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Argentina, and China). In addition, the report includes a 10-year epidemiological forecast of the diagnosed prevalent cases of hemophilia, segmented by type (A and B), sex, and age (starting at ages 0 years) in these markets.
- The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
- Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
- Identify the hemophilia type that is most important to your marketing plans.

【レポートの目次】

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 11
3.4 Forecast Methodology 13
3.4.1 Sources Used 13
3.4.2 Sources Not Used 14
3.4.3 Forecast Assumptions and Methods 15
3.5 Epidemiological Forecast for Hemophilia A (2014-2024) 19
3.5.1 Diagnosed Prevalent Cases of Hemophilia A 19
3.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age 20
3.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex 22
3.5.4 Age-Standardized Diagnosed Prevalence of Hemophilia A 24
3.6 Epidemiological Forecast for Hemophilia B (2014-2024) 26
3.6.1 Diagnosed Prevalent Cases of Hemophilia B 26
3.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age 27
3.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex 29
3.6.4 Age-Standardized Diagnosed Prevalence of Hemophilia B 31
3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2014-2024) 32
3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 32
3.7.2 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex 34
3.8 Discussion 36
3.8.1 Conclusions on Epidemiological Trends 36
3.8.2 Limitations of the Analysis 37
3.8.3 Strengths of the Analysis 38
4 Appendix 39
4.1 Bibliography 39
4.2 About the Authors 41
4.2.1 Epidemiologists 41
4.2.2 Reviewers 42
4.2.3 Global Director of Epidemiology and Health Policy 42
4.2.4 Global Head of Healthcare 43
4.3 About GlobalData 44
4.4 About EpiCast 44
4.5 Disclaimer 45

1.1 List of Tables
Table 1: Relationship of Bleeding Severity with Clotting Factor Level 9
Table 2: Hemophilia - Risk Factors and Comorbidities 11
Table 3: 9MM, Diagnosed Prevalence of Hemophilia A (per 100,000 Population), Both Sexes, All Ages, 2004-2013 12
Table 4: 9MM, Diagnosed Prevalence of Hemophilia B (per 100,000 Population), Both Sexes, All Ages, 2004-2013 12
Table 5: 9MM, Sources and Diagnosed Prevalence Data for Hemophilia A and B 13
Table 6: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024 19
Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2014 21
Table 8: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2014 23
Table 9: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024 26
Table 10: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, Row (%), 2014 28
Table 11: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, Row (%), 2014 30
Table 12: 9MM, Diagnosed Prevalent Cases of Hemophilia, Both Sexes, All Ages, N, 2014-2024 33
Table 13: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, Row (%), 2014 35

1.2 List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024 20
Figure 2: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, 2014 22
Figure 3: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, 2014 24
Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (per 100,000 Population), by Sex, 2014 25
Figure 5: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024 27
Figure 6: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, 2014 29
Figure 7: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, 2014 31
Figure 8: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia B (per 100,000 Population), by Sex, 2014 32
Figure 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2014-2024 34
Figure 10: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, 2014 36

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 血友病の疫学的予測(~2024)(EpiCast Report: Hemophilia - Epidemiology Forecast to 2024)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆